Efficacy of Modified Shengjiangsan in Treatment of Chest and Hypochondrium Fluid-retention Type Tuberculous Pleurisy and Effect on Pleural effusion, Immune Function, T-lymphocytes and Inflammatory Factors

WANG Tao; TIAN Yan-qing; WANG Xiu-zheng; GAO Yun; GAO Yue-yun; ZHANG Zhan-ying; ZHAO Yong-chen

doi:10.13422/j.cnki.syfjx.2018010169

您当前的位置：

首页 >

文章列表页 >

Efficacy of Modified Shengjiangsan in Treatment of Chest and Hypochondrium Fluid-retention Type Tuberculous Pleurisy and Effect on Pleural effusion, Immune Function, T-lymphocytes and Inflammatory Factors

更新时间：2024-01-04

- Efficacy of Modified Shengjiangsan in Treatment of Chest and Hypochondrium Fluid-retention Type Tuberculous Pleurisy and Effect on Pleural effusion, Immune Function, T-lymphocytes and Inflammatory Factors
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 24, Issue 1, Pages: 169-173(2018)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfjx.2018010169
  CLC： R259
- Published：2018
- 稿件说明：
移动端阅览
WANG Tao, TIAN Yan-qing, WANG Xiu-zheng, et al. Efficacy of Modified Shengjiangsan in Treatment of Chest and Hypochondrium Fluid-retention Type Tuberculous Pleurisy and Effect on Pleural effusion, Immune Function, T-lymphocytes and Inflammatory Factors[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(1): 169-173.
DOI：

WANG Tao, TIAN Yan-qing, WANG Xiu-zheng, et al. Efficacy of Modified Shengjiangsan in Treatment of Chest and Hypochondrium Fluid-retention Type Tuberculous Pleurisy and Effect on Pleural effusion, Immune Function, T-lymphocytes and Inflammatory Factors[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(1): 169-173. DOI： 10.13422/j.cnki.syfjx.2018010169.

摘要

目的：探讨饮停胸胁型结核性胸膜炎（TBP）患者应用加味升降散对其胸腔积液腺苷脱氨酶（adenosine deaminase，ADA），免疫功能，T淋巴细胞及炎症因子水平的影响。方法：选取河北大学附属医院2014年3月-2016年3月收治的结核性胸膜炎患者120例，按随机数字表法分为两组。两组均予以胸腔穿刺抽液+抗结核药物常规治疗；观察组在此基础上，给予加味升降散治疗。记录并比较两组连续治疗2个月时胸腔积液ADA免疫功能及炎症因子指标，同时对比中医证候积分及临床疗效。结果：治疗2个月后，观察组总有效率为91.11%，较对照组总有效率73.33%明显升高（P<0.05）；两组治疗2个月时胸腔积液ADA水平明显低于治疗前（P<0.05）；与对照组比较，观察组治疗2个月时胸腔积液ADA水平明显降低（P<0.05）；治疗2个月后，两组免疫球蛋白（IgA，IgG，IgM）和T淋巴细胞（CD3+，CD4+）较治疗前升高，转化生长因子-β1（transforming growth factor-β，TGF-β1），白细胞介素-6（interleukin-6，IL-6），白细胞介素-8（interleukin-8，IL-8）及肿瘤坏死因子-α（tumor necrosis factor-α，TNF-α）含量较治疗前明显降低（P<0.05）；两组患者发热、胸胁痛、气促、咳嗽中医证候评分明显降低（P<0.05）；与对照组比较，观察组治疗后免疫球蛋白（IgA，IgG，IgM）和T淋巴细胞（CD3+，CD4+）明显升高，TGF-β1，IL-6，IL-8，TNF-α含量降低，发热、胸胁痛、气促、咳嗽中医证候评分降低（P<0.05）；观察组胸水引流量、胸水消失时间、住院时间及胸膜厚度均低于对照组（P<0.05）；所有患者均获得随访，无病例脱落现象，两组间不良反应发生率比较差异无统计学意义。结论：加味升降散治疗饮停胸胁型结核性胸膜炎疗效确切，降低胸腔积液ADA水平及炎症因子水平，提高免疫功能。

Abstract

Objective:To investigate the effect of modified Shengjiangsan on pleural effusion adenosine deaminase (ADA)

immune function

T lymphocytes and inflammatory factors in the treatment of chest and hypochondrium fluid-retention type tuberculous pleurisy. Method:The 120 patients with tuberculous pleurisy from our hospital in March 2014 to March 2016 were selected and randomly divided into 2 groups. The control group received thoracic cavity drainage+anti-tuberculosis routine drug treatment

and observation group received received modified Shengjiangsan based on the treatment in control group. Pleural effusion

inflammatory factors

immune index

Chinese medicine syndrome scores and clinical curative effect were compared after the treatment for 2 months. Result:After treatment for 2 months

the total effective rate was 91.11% in observation group

significantly higher than 73.33% in control group (P<0.05); pleural effusion ADA levels were significantly lower than the levels before treatment in both groups (P<0.05)

and the level in observation group was significantly lower than that in control group after treatment (P<0.05). After treatment for 2 months

the immunoglobulin(IgA

IgG

IgM) and T lymphocytes (CD3+

CD4+) were increased

while the levels of TGF-β1

IL-6

IL-8 and TNF-α were decreased

and the symptom scores of fever

chest pain

shortness of breath and cough were decreased in both groups (P<0.05); as compared with control group

the levels of immunoglobulin (IgA

IgG

IgM) and T lymphocytes (CD3+

CD4+) in observation group were higher

while the levels of TGF-β1

IL-6

IL-8 and TNF-α were lower

and the symptom scores of fever

chest pain

shortness of breath and cough were lower(P<0.05). Pleural effusion drainage

pleural effusion disappearing time

hospitalization time and pleural thickness in observation group were lower than those in control group (P<0.05). All the patients were followed up

no cases of falling

with no statistically significant difference in adverse reactions incidence between two groups. Conclusion:With clear effect in the treatment of tuberculous pleurisy

modified Shengjiangsan can significantly reduce the thickness and inflammatory factors of the pleura

and improve immune function.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical Efficacy of Qimai Qinlou Prescription in Treating Elderly Community-acquired Pneumonia （Non-severe） with Qi and Yin Deficiency and Phlegm-heat Obstructing Lung Syndrome

Clinical Efficacy on Addition and Subtraction Therapy of Zhibai Dihuangwan Combined with Wulingsan on Children with Refractory Nephrotic Syndrome

Effect on Treatment of Addition and Subtraction Therapy of Zhuyu Zhixuetang to Chronic Endometritis with Syndrome of Qi Deficiency and Blood Stasis

Clinical Efficacy and Mechanism of Modified Yihuo Qinggan Tuiyi Tang in Treating Herpes Simplex Keratitis with Liver Meridian and Wind-heat

Comprehensive Optimization of Rehabilitation Measures of Traditional Chinese Medicine to Elderly Patients with COPD at Stable Period

Related Author

LIU Yishu

HUANG Qiuyue

ZHU Huan

LI Hanjiao

WEI Ruoheng

Jia HUANG

Zheng WANG

Ji-hong ZHANG

Related Institution

The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine（TCM）

The Second Affiliated Hospital of Hainan Medical College

Sinan County People's Hospital of Guizhou Province

Guizhou University of TCM

West China Second Hospital，Sichuan University， Key Laboratory of Maternal and Child Related Diseases and Birth Defects

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰